I'm working to shed light on financial relationships between drug companies and doctors. I've conducted oversight, and I'm working for passage of legislation that would require public reporting by drug companies of the money they give to doctors for consulting, travel, speeches, meals and other activities. The public interest is clear. We all rely on the advice of doctors, and leading researchers influence the practice of medicine. Taxpayers spend billions of dollars each year on prescription drugs and devices through Medicare and Medicaid. The National Institutes of Health distributes $24 billion annually in federal research grants. So the public has a right to know about financial relationships between doctors and drug companies.
Related News Stories and Editorial Comments:
Dr. Stephen L. Ondra, Director of Spine Surgery, Northwestern University
Dr. Melissa DelBello, Associate Professor of Psychiatry, University of Cincinnati
Dr. Alan Schatzberg, Chairman of the Department of Psychiatry, Stanford University
Dr. Joseph Biederman, Professor of Psychiatry, Harvard University
Dr. Timothy E. Wilens, Associate Professor of Psychiatry, Harvard University
Dr. Charles Nemeroff, Chairman of Psychiatry, Emory University
Dr. Karen Wagner, Robert L. Stubblefield Professor and Vice Chair in the Department of Psychiatry and Behavioral Sciences and Director of the Division of Child and Adolescent Psychiatry at the University of Texas Medical Branch in Galveston
Dr. Augustus John Rush, Vice Dean of Clinical Sciences, Duke-NUS Graduate Medical School Singapore
Dr. Frederick K. Goodwin, Host, "The Infinite Mind"
Thomas Zdeblick, Professor and Chairman, Department of Orthopedics & Rehabilitation, University of Wisconsin
Dr. David Polly, Professor and Chief of the Spine Service, University of Minnesota
Dr. Timothy Kuklo, Associate Professor - Orthopaedic Surgery and Neurological Surgery, Washington University School of Medicine
Dr. Jeffrey C. Wang, UCLA
Editorials and Op-Eds: